Beckmann, J. ., Siripurapu, K. ., , Horton, D. ., Denehy, E. ., Vartak, A. ., … Bardo, M. . (2010). The novel pyrrolidine nor-lobelane analog UKCP-110 cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics, 335(3), 841-51. https://doi.org/10.1124/jpet.110.172742

Smith, A. ., Pivavarchyk, M. ., Wooters, T. ., Zhang, Z. ., Zheng, G. ., McIntosh, J. ., … Dwoskin, L. . (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)

Beckmann, J. ., Denehy, E. ., Zheng, G. ., Crooks, P. ., Dwoskin, L. ., & Bardo, M. . (2012). The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology, 220(2), 395-403. https://doi.org/10.1007/s00213-011-2488-9

Alvers, K. ., Beckmann, J. ., Zheng, G. ., Crooks, P. ., Dwoskin, L. ., & Bardo, M. . (2012). The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology, 224(2), 255-62. https://doi.org/10.1007/s00213-012-2748-3

Dwoskin, L. ., Smith, A. ., Wooters, T. ., Zhang, Z. ., Crooks, P. ., & Bardo, M. . (2009). Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochemical Pharmacology, 78(7), 732-43. https://doi.org/10.1016/j.bcp.2009.06.002 (Original work published 2009)

Dwoskin, L. ., Pivavarchyk, M. ., Joyce, B. ., Neugebauer, N. ., Zheng, G. ., Zhang, Z. ., … Crooks, P. . Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebraska Symposium on Motivation. Nebraska Symposium on Motivation, 55, 31-63. https://doi.org/10.1007/978-0-387-78748-0_4 (Original work published 2009)

Rahman, S. ., Neugebauer, N. ., Zhang, Z. ., Crooks, P. ., Dwoskin, L. ., & Bardo, M. . (2008). The novel nicotinic receptor antagonist N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. European Journal of Pharmacology, 601(1-3), 103-5. https://doi.org/10.1016/j.ejphar.2008.10.037 (Original work published 2008)

Wooters, T. ., Smith, A. ., Pivavarchyk, M. ., Siripurapu, K. ., McIntosh, J. ., Zhang, Z. ., … Dwoskin, L. . (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x

Rahman, S. ., Zhang, Z. ., Papke, R. ., Crooks, P. ., Dwoskin, L. ., & Bardo, M. . (2008). Region-specific effects of N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. British Journal of Pharmacology, 153(4), 792-804. https://doi.org/10.1038/sj.bjp.0707612

Dwoskin, L. ., Joyce, B. ., Zheng, G. ., Neugebauer, N. ., Manda, V. ., Lockman, P. ., … Crooks, P. . (2007). Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochemical Pharmacology, 74(8), 1271-82. https://doi.org/10.1016/j.bcp.2007.07.021 (Original work published 2007)